Repligen to acquire BioLife Solutions for about $1.5 billion
Repligen announced a cash-and-stock deal to acquire BioLife Solutions for about $1.5 billion, expanding into the fast-growing cell-therapy equipment market. The acquisition could unlock strategic value for BioLife and accelerate cross-sell opportunities with Repligen's customer base, but closing depends on customary regulatory approvals and financing.
View signal analysis